Dominant-negative Ikaros cooperates with BCR-ABL1 to induce human acute myeloid leukemia in xenografts

Leukemia

Volumn 29, Issue 1, 2015, Pages 177-187

  Theocharides, A P A ^a,b,c   Dobson, S M ^a,b   Laurenti, E ^a,b   Notta, F ^a,b   Voisin, V ^b   Cheng, P Y ^a   Yuan, J S ^d   Guidos, C J ^d   Minden, M D ^a,b,e   Mullighan, C G ^f   Torlakovic, E ^a,g   Dick, J E ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^g TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; GLYCOPHORIN A; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IKAROS TRANSCRIPTION FACTOR; INTERLEUKIN 3; STAT PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN; IKZF1 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOMINANT GENE; EXPERIMENTAL LEUKEMIA; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; GENE VECTOR; GRANULOCYTIC SARCOMA; HUMAN; LEUKEMOGENESIS; MOUSE; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PRE B LYMPHOCYTE; TUMOR XENOGRAFT; UMBILICAL CORD BLOOD; WILD TYPE; XENOTRANSPLANTATION; CELL LINE; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; PATHOLOGY; XENOGRAFT;

CELL LINE; CELL PROLIFERATION; FUSION PROTEINS, BCR-ABL; GENES, DOMINANT; HETEROGRAFTS; HUMANS; IKAROS TRANSCRIPTION FACTOR; LEUKEMIA, MYELOID, ACUTE;

EID: 84920687465     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.150     Document Type: Article

References (48)

1. Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010; 70: 447-452.
2. Klampfl T, Harutyunyan A, Berg T, Gisslinger B, Schalling M, Bagienski K et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood 2011; 118: 167-176.
3. Sokal JE. Evaluation of survival data for chronic myelocytic leukemia. Am J Hematol 1976; 1: 493-500.
4. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986; 233: 212-214.
5. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004; 103: 4010-4022.
6. Grossmann V, Kohlmann A, Zenger M, Schindela S, Eder C, Weissmann S et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia 2011; 25: 557-560.
7. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008; 453: 110-114.
8. Rizo A, Horton SJ, Olthof S, Dontje B, Ausema A, van Os R et al. BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34 + cells. Blood 2010; 116: 4621-4630.
9. Chalandon Y, Jiang X, Christ O, Loutet S, Thanopoulou E, Eaves A et al. BCR-ABL-transduced human cord blood cells produce abnormal populations in immuno-deficient mice. Leukemia 2005; 19: 442-448.
10. Kennedy JA, Barabe F. Investigating human leukemogenesis: from cell lines to in vivo models of human leukemia. Leukemia 2008; 22: 2029-2040.
11. Iacobucci I, Storlazzi CT, Cilloni D, Lonetti A, Ottaviani E, Soverini S et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood 2009; 114: 2159-2167.
12. Jager R, Gisslinger H, Passamonti F, Rumi E, Berg T, Gisslinger B et al. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia 2010; 24: 1290-1298.
13. Cazzaniga G, van Delft FW, Lo Nigro L, Ford AM, Score J, Iacobucci I et al. Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph + acute lymphoblastic leukemia. Blood 2011; 118: 5559-5564.
14. Sun L, Liu A, Georgopoulos K. Zinc finger-mediated protein interactions modulate Ikaros activity, a molecular control of lymphocyte development. EMBO J 1996; 15: 5358-5369.
15. Nacheva EP, Grace CD, Brazma D, Gancheva K, Howard-Reeves J, Rai L et al. Does BCR/ABL1 positive acute myeloid leukaemia exist? Br J Haematol 2013; 161: 541-550.
16. Klug CA, Morrison SJ, Masek M, Hahm K, Smale ST, Weissman IL. Hematopoietic stem cells and lymphoid progenitors express different Ikaros isoforms, and Ikaros is localized to heterochromatin in immature lymphocytes. Proc Natl Acad Sci USA 1998; 95: 657-662.
17. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360: 470-480.
18. Iacobucci I, Iraci N, Messina M, Lonetti A, Chiaretti S, Valli E et al. IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. PLoS One 2012; 7: e40934.
19. Virely C, Moulin S, Cobaleda C, Lasgi C, Alberdi A, Soulier J et al. Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia. Leukemia 2010; 24: 1200-1204.
20. Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011; 17: 1086-1093.
21. Merlos-Suarez A, Barriga FM, Jung P, Iglesias M, Cespedes MV, Rossell D et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011; 8: 511-524.
22. Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 2010; 304: 2706-2715.
23. Winandy S, Wu P, Georgopoulos K. A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma. Cell 1995; 83: 289-299.
24. Schjerven H, McLaughlin J, Arenzana TL, Frietze S, Cheng D, Wadsworth SE et al. Selective regulation of lymphopoiesis and leukemogenesis by individual zinc fingers of Ikaros. Nat Immunol 2013; 14: 1073-1083.
25. Guenechea G, Gan OI, Dorrell C, Dick JE. Distinct classes of human stem cells that differ in proliferative and self-renewal potential. Nat Immunol 2001; 2: 75-82.
26. Doulatov S, Notta F, Eppert K, Nguyen LT, Ohashi PS, Dick JE. Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development. Nat Immunol 2010; 11: 585-593.
27. Wang JC, Warner JK, Erdmann N, Lansdorp PM, Harrington L, Dick JE. Dissociation of telomerase activity and telomere length maintenance in primitive human hematopoietic cells. Proc Natl Acad Sci USA 2005; 102: 14398-14403.
28. Chung KY, Morrone G, Schuringa JJ, Plasilova M, Shieh JH, Zhang Y et al. Enforced expression of NUP98-HOXA9 in human CD34(+) cells enhances stem cell proliferation. Cancer Res 2006; 66: 11781-11791.
29. Barabe F, Kennedy JA, Hope KJ, Dick JE. Modeling the initiation and progression of human acute leukemia in mice. Science 2007; 316: 600-604.
30. Kennedy JA, Barabe F, Patterson BJ, Bayani J, Squire JA, Barber DL et al. Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo. Proc Natl Acad Sci USA 2006; 103: 16930-16935.
31. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
32. Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One 2010; 5: e13984.
33. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 2011; 27: 431-432.
34. Laurenti E, Doulatov S, Zandi S, Plumb I, Chen J, April C et al. The transcriptional architecture of human hematopoiesis reveals novel regulators governing lymphoid commitment. Nat Immunol 2013; 14: 756-763.
35. Chalandon Y, Jiang X, Hazlewood G, Loutet S, Conneally E, Eaves A et al. Modulation of p210(BCR-ABL) activity in transduced primary human hematopoietic cells controls lineage programming. Blood 2002; 99: 3197-3204.
36. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues, Vol. 2. IARC: Lyon, France, 2008, pp 1-439.
37. Krause DS, Fulzele K, Catic A, Sun CC, Dombkowski D, Hurley MP et al. Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat Med 2013; 19: 1513-1517.
38. Wunderlich M, Chou FS, Link KA, Mizukawa B, Perry RL, Carroll M et al. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia 2010; 24: 1785-1788.
39. Ng SY, Yoshida T, Zhang J, Georgopoulos K. Genome-wide lineage-specific tran-scriptional networks underscore Ikaros-dependent lymphoid priming in hema-topoietic stem cells. Immunity 2009; 30: 493-507.
40. Panteli KE, Hatzimichael EC, Bouranta PK, Katsaraki A, Seferiadis K, Stebbing J et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol 2005; 130: 709-715.
41. Chen W, Kumar AR, Hudson WA, Li Q, Wu B, Staggs RA et al. Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. Cancer Cell. 2008; 13: 432-440.
42. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006; 442: 818-822.
43. Yagi T, Hibi S, Takanashi M, Kano G, Tabata Y, Imamura T et al. High frequency of Ikaros isoform 6 expression in acute myelomonocytic and monocytic leukemias: implications for up-regulation of the antiapoptotic protein Bcl-XL in leukemo-genesis. Blood 2002; 99: 1350-1355.
44. Minami Y, Stuart SA, Ikawa T, Jiang Y, Banno A, Hunton IC et al. BCR-ABL-trans-formed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci USA 2008; 105: 17967-17972.
45. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al. Granu-locyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351: 657-667.
46. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481: 157-163.
47. Yoshida T, Ng SY, Georgopoulos K. Awakening lineage potential by Ikaros-mediated transcriptional priming. Curr Opin Immunol 2010; 22: 154-160.
48. Reynaud D, Pietras E, Barry-Holson K, Mir A, Binnewies M, Jeanne M et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 2011; 20: 661-673.